ExodusPoint Capital Management LP has recently increased its stake in Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in the development of T cell therapies for cancer treatment. According to the company’s latest filing with the Securities and Exchange Commission (SEC), ExodusPoint Capital Management LP now owns 413,764 shares of Autolus Therapeutics, representing a 21.1% growth during the first quarter.
This increase in shares amounted to an additional 72,044 shares purchased by ExodusPoint Capital Management LP during the said period. As of the most recent filing with the SEC, this position was valued at approximately $761,000, accounting for around 0.24% of Autolus Therapeutics’ total worth.
Autolus Therapeutics is primarily focused on advancing its clinical-stage programs to combat various forms of cancer using innovative T cell therapies. One such program is obecabtagene autoleucel (AUTO1), which is currently undergoing Phase 1b/2 clinical trials for the treatment of adult acute lymphoblastic leukemia (ALL).
Additionally, Autolus Therapeutics is conducting a Phase 1 clinical trial for AUTO1/22 in pediatric patients with relapsed or refractory ALL. These investigational therapies target CD19 and demonstrate promise in providing potential solutions for difficult-to-treat cancers.
Another notable program from Autolus Therapeutics is AUTO4, a programmed T cell investigational therapy designed specifically to treat peripheral T-cell lymphoma by targeting TRBC1 and TRBC2. While still in development stages, this therapy shows potential for improving patient outcomes in this particular indication.
Furthermore, Autolus Therapeutics is researching AUTO6NG as a programmed T cell investigational therapy that targets GD2 and aims to treat neuroblastoma. Although AUTO6NG is currently in preclinical trials, it represents an exciting prospect for addressing such a challenging pediatric cancer.
Lastly, Autolus Therapeutics’ AUTO8 is undergoing Phase I clinical trials for the treatment of multiple myeloma. Through the development of this product candidate, Autolus Therapeutics aims to expand its therapeutic offerings and provide potential treatments for patients with this hematological malignancy.
As a result of the recent increase in shares held by ExodusPoint Capital Management LP, Autolus Therapeutics gains further recognition and support from seasoned investors in the financial sector. This type of investment signifies confidence in the company’s scientific advancements and research efforts to combat cancer through the use of T cell therapies.
Autolus Therapeutics’ collaboration with ExodusPoint Capital Management LP opens up opportunities for increased funding, which will undoubtedly aid the company in driving forward its clinical programs and potentially revolutionizing cancer treatment. It is essential to acknowledge the significance of continued investment in biopharmaceutical companies like Autolus Therapeutics, as they play a vital role in advancing medical science and bringing innovative therapies to patients worldwide.
In conclusion, ExodusPoint Capital Management LP’s decision to expand its position in Autolus Therapeutics plc demonstrates growing interest and confidence in the company’s advancements within the field of T cell therapies for cancer treatment. With an array of promising clinical-stage programs targeting various types of cancer, Autolus Therapeutics remains at the forefront of innovative research aimed at improving patient outcomes and revolutionizing cancer care.
Autolus Therapeutics plc
AUTL
Buy
Updated on: 07/12/2023
Healthy 
Price to earnings ratio: Sell 
Hedge Funds and Institutional Investors Show Growing Interest in Autolus Therapeutics
In recent times, several hedge funds have been making significant changes to their positions in Autolus Therapeutics, a prominent biopharmaceutical company. Cetera Investment Advisers, for instance, has experienced an 8.3% increase in its holdings during the first quarter of this year. As a result, the firm now possesses 124,300 shares of Autolus Therapeutics’ stock, equating to a value of $518,000. This was made possible after acquiring an additional 9,550 shares in the last quarter.
Moreover, Nantahala Capital Management LLC also witnessed growth in its holdings. Their ownership stake in Autolus Therapeutics spiked by 6.6% during the first quarter, resulting in them currently owning approximately 4,346,327 shares of the company’s stock valued at $18,124,000. They obtained an additional 268,818 shares within this period.
UBS Group AG also experienced substantial growth with an astounding increase of 716.1% in their holdings during the same quarter. They currently possess a total of 73,858 shares valued at $308,000 after acquiring an extra 64,808 shares.
Additionally, Goldman Sachs Group Inc.’s holdings rose by 144.8% in the first quarter with AUtolis therapeutics stock having reached $1,5661 looking back on it it grew more by nearly double its market value than expected five months ago based on previous data survey and analysis hence this is very encouraging to all Delgado Pharmaceuticals Clinics customers
Finally,Renaissance Technologies LLC entered the sector and acquired a new position in Autolus Therapeutics worth approximately $36 million during the second quarter.
Overall,Hedge funds and other institutional investors presently own a remarkable majority share of approximately 64.78% of Autolus Therapeutics’ stock.
Separately from these developments within hedge funds and institutional investors, Truist Financial raised its target price for Autolus Therapeutics from $6 to $9 and bestowed the company with a “buy” rating in a recent report on August 17th. The market analysts chimed in as well, with five research analysts so far giving the stock a buy rating. According to data obtained from Bloomberg, Autolus Therapeutics currently holds an average rating of “Buy” and a consensus target price of $7.80.
As for the financial standing of Autolus Therapeutics itself, shares for the company (NASDAQ:AUTL) opened at $3.14 on Wednesday. Over the past year, the stock has experienced fluctuations between its low point of $1.60 and its high point of $3.54. Presently, the fifty-day simple moving average stands at $2.87, while the 200-day simple moving average is slightly lower at $2.46.
Considering market capitalization, Autolus Therapeutics currently holds a value of approximately $545.36 million. The company’s P/E ratio is -2.64 and it possesses a beta rating of 1.48.
Looking back on their recent quarterly earnings report issued on August 3rd, Autolus Therapeutics presented an EPS (earnings per share) figure of ($0.26), subsequently failing to meet the anticipated consensus estimate by($0.04). Industry experts analyze that sell-side analysts expect Autolus Therapeutics plc to post negative earnings per share amounting to -0.97 for this fiscal year.
In conclusion, Autolus Therapeutics has attracted significant attention from hedge funds and institutional investors due to its potential growth prospects in the biopharmaceutical sector.
Discussion about this post